Klaus Leitl is an Austrian artist who makes insects. Incredibly lifelike insects such as the Mayfly shown above. He posted some examples on the Formlabs forums, and they quickly took notice. They’ve posted an interview with him about how 3D printing is changing his craft. The interview and accompanying pictures are quite interesting. Not only because the insects look really cool, but because Klaus shares considerable insight into the way the entire process has changed now that he has a 3D printer.
Some of the points that I found most interesting in the article were:
He isn’t simply printing everything
The “holy grail” in many 3D printing hobbyists mind are things that can be printed all at once and simply lifted off the print bed as a finished item. Just like a replicator from Star Trek. We can all agree that his pieces are extremely impressive but he is also spending a considerable amount of time assembling and finishing them. He also has many parts that he still needs to make by hand, such as super thin wings like the ones shown above, or very thin antennae.
Multiple models are incredibly faster with a 3D printer
The old process involved hand sculpting a model for every size and variation of insect he was going to create. The 3D printer allows him to simply scale the parts and assemble them in slightly different poses. When he needs to create 3 or 4 different sizes of the same insect, this adds up to be an incredible time savings.
Anatomical revisions
The old days, an entomologist would look at his final sculpture and point out inaccuracies. Now he can tweak them at a digital stage.
Take a few minutes to read the full interview and look at the rest of the pictures.
4 thoughts on “Incredible Insects On The Form 1+ 3D Printer”
Comments are closed.
ADVERTISEMENT
Join Make: Community Today
Reblogged this on enginerd2 and commented:
Super awesome.
Phase III clinical study of complicated intra-abdominal infections within AstraZeneca’s new antibiotic drugs CAZ-AVI treatment was a complete success
August 21, 2014 News – Phase III clinical study AstraZeneca recently announced the development of new antibiotics CAZ-AVI (ceftazidime-avibactam) treatment of complicated intra-abdominal infections (cIAI) achieved satisfactory results.Caspofungin Acetate， The results showed that CAZ-AVI in the treatment of cIAI patients (including cephalosporins by anti-bacteria cIAI statin-induced) when equally effective with meropenem.
The phase III clinical study using the RECLAIM-1 and RECLAIM-2 experimental design. Active ingredients CAZ-AVI is constituted by the treatment of serious bacterial infections cephalosporin statins and β-lactamase inhibitor new avibactam. CAZ-AVI in avibactam statins can protect cephalosporins are not decomposed by the resistant bacteria secreted β-lactamase, thereby maintaining bacterial toxicity. The antibiotic used to treat a range of drug-resistant Gram-negative bacteria. The clinical study also evaluated different doses of CAZ-AVI in clinical efficacy and safety. The results showed that the clinical efficacy of meropenem CAZ-AVI, the patients were randomly assigned basically administered 28-35 days in recovery.Micafungin sodium ， While its side effects are not higher than that of meropenem, clinical CAZ-AVI showing the main side effects were diarrhea, vomiting, nausea and fever.
AstraZeneca said researchers excited about the results, but also revealed that currently CAZ-AVI research hospital for urinary tract infections and pneumonia also is well underway.
Ten years ago, due to lower profits and diverse variety of antibiotics, including many pharmaceutical giant AstraZeneca all have to exit the antibiotics market.Febuxostat， However, in recent years, drug-resistant bacteria in the global blowout situation, so that these pharmaceutical giants and national medical management department aware of a serious crisis and opportunity, many pharmaceutical manufacturers have re-return to the market, devote their energies to the development of new antibiotics.
Amazing